Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Proof that Patterson is unblinded: the IVRS number

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155149
(Total Views: 790)
Posted On: 06/07/2020 5:05:12 PM
Posted By: havasu78
Re: blafarm #36978
Proof that Patterson is unblinded: the IVRS number

OK, so blafarm's post includes several pastes from investorshub.

One of those pasted posts identifies something called an "IVRS" number.

The investorshub poster further claims that every clinical trial sample includes a unique patient identifier, known as the "IVRS" number.

IVRS stands for Interactive Voice Response System. Apparently the unique patient identifier got its start as a code word which grants medical care practitioners acces to a particular human clinical trial and or supply system through an automated attendant.

So it looks like the FDA does have a protocol, and that protocol does include unique patient identifier on every blood sample vial.

Which means that Patterson can easily tracky patients through the study.

And when the primary endpoint is mortality, Patterson easily computes the trial primary endpoint, including p-value, as he recognizes that if the samples stop coming in then probably the patient died.

Patterson has sufficient experience that he can compute the severe/critical mortality primary endpoint in his head.

Heck, he probably re-computes the primary trial endpoint p-value every evening just for fun.

Now the only remaining question is whether he is allowed to tell anyone about this.

It is notable that Patterson is the ONLY person who can compute the primary endpoint in realy time because 1) Patterson is the ONLY person who has acces to all patients, and 2) Patterson MAY BE the only person who has access to the CCR5 receptor occupancy assay needed to discriminate between leronlimab and placebo.


(5)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us